CIRM lures biotechs with $20M for stem cell teams

California's Institute of Regenerative medicine is planning to provide $20 million to each of 10 to 12 research teams that can be in the clinic with a new therapy inside of four years. Agency president Alan Trounson says that it's time to start moving stem cell work out of the lab and into human trials. Report

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.